Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)
CUSIP: 45719W205
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 128,205,929
- Total 13F shares
- 836,496
- Share change
- +630,938
- Total reported value
- $1,021,038
- Price per share
- $1.21
- Number of holders
- 12
- Value change
- +$723,392
- Number of buys
- 7
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 45719W205?
CUSIP 45719W205 identifies IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 45719W205:
Top shareholders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BLAIR WILLIAM & CO/IL |
13F
|
Company |
0.06%
|
76,601
|
$165,458 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.02%
|
28,692
|
$62,023 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.02%
|
22,616
|
$48,851 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
21,422
|
$46,000 | — | 31 Mar 2024 | |
| Redmond Asset Management, LLC |
13F
|
Company |
0.02%
|
19,560
|
$42,250 | — | 31 Mar 2024 | |
| Joseph Frattaroli |
3/4/5
|
Cheif Financial Officer |
—
mixed-class rows
|
138,091
mixed-class rows
|
$38,473 | — | 01 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.01%
|
16,724
|
$36,124 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.01%
|
10,084
|
$21,781 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
3,214
|
$6,942 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
2,771
|
$5,985 | — | 31 Mar 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
2,000
|
$4,320 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,667
|
$3,601 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
207
|
$447 | — | 31 Mar 2024 | |
| Elizabeth G. O'Farrell |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 24 Jun 2022 |
Institutional Holders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) as of Q2 2024
As of 30 Jun 2024,
Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
836,496 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, BLAIR WILLIAM & CO/IL, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, STATE STREET CORP, Tower Research Capital LLC (TRC), MORGAN STANLEY, and MATHER GROUP, LLC..
This page lists
12
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
12
Q2 2024 holders
12
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.